Department of Neurological Surgery, University of California at San Francisco, 505 Parnassus Avenue, San Francisco, California 94143, USA.
J Clin Neurosci. 2009 Dec;16(12):1547-51. doi: 10.1016/j.jocn.2009.05.003. Epub 2009 Sep 30.
Most data regarding survival in patients with chondrosarcoma are limited to case studies and small series performed at single institutions. A systematic review was performed to study the relationship between potential prognostic factors and survival. The survival rates were analyzed according to modality of treatment, treatment history, histological subtype, and histological grade. A total of 560 patients with intracranial chondrosarcoma were analyzed. Median follow-up time was 60 months. The 5-year mortality among all patients was 11.5% with median survival of 24 months. Mortality at 5 years was significantly greater for patients with tumors of higher grade, or of the mesenchymal subtype, or who had received surgical resection alone. The results of our systematic review provide useful data in predicting survival among intracranial chondrosarcoma patients.
大多数关于软骨肉瘤患者生存的数据仅限于单机构进行的病例研究和小系列研究。进行了系统评价以研究潜在预后因素与生存之间的关系。生存率根据治疗方式、治疗史、组织学亚型和组织学分级进行分析。共分析了 560 例颅内软骨肉瘤患者。中位随访时间为 60 个月。所有患者的 5 年死亡率为 11.5%，中位生存时间为 24 个月。高级别肿瘤、间充质亚型或仅接受手术切除的患者 5 年死亡率显著更高。我们的系统评价结果为预测颅内软骨肉瘤患者的生存提供了有用的数据。
